Addex Therapeutics LtdADXNNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -83.57% | -99.02% | -100.00% | -68.45% | -44.79% |
| Gross Profit Growth | -83.57% | -99.02% | -100.00% | -271.83% | -44.79% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -114.30% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -116.41% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -115.38% | +0.00% |
| Weighted Average Shares Growth | +26.21% | +2.72% | +0.83% | -11.29% | +15.53% |
| Weighted Average Shares Diluted Growth | +26.21% | +2.72% | +0.83% | -5.61% | +15.53% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +38.34% | -89.74% | -84.29% | -93.76% | -90.08% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +98.24% | +130.04% | +184.51% | -37.90% | -39.75% |
| Book Value per Share Growth | +122.21% | +722.49% | +0.00% | -35.73% | -53.37% |
| Debt Growth | -86.46% | -87.80% | +14.26% | +19.28% | -16.49% |
| R&D Expense Growth | -81.52% | -101.37% | -81.81% | -62.87% | +9.52% |
| SG&A Expenses Growth | -28.85% | -84.71% | -21.63% | -18.77% | +36.37% |